Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema

Assistance Publique - Hôpitaux de Paris300 enrolled

Overview

The aim of this study is to describe the natural history of patients with alpha-1 antitrypsin associated emphysema and to figure out associated prognostic factors.

All patients who suffer from this disease are followed every 6 months during a 5 years period. FEV1 decline is the primary endpoint. Quality of life assessed using the Saint George's Respiratory Questionary is recorded too.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Alpha 1-Antitrypsin Deficiency Emphysema

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Serum alpha one antitrypsin \< 0.8 g/l * Emphysema diagnosed by CT scan * Adult * Obstructive disorder Exclusion Criteria: * Liver or lung transplantation

Locations (1)

Departement d'épidémiologie, Hôpital Bichat

Paris, France

RECRUITING

Central Contacts

Gabriel Thabut, MD

CONTACT

1 40 87 57 12 g.thabut@bch.aphp.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.